IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

PARSIPPANY, N.J.--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company's New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy

PARSIPPANY, N.J.--( BUSINESS WIRE )--IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the Company's business strategy and in overseeing the development and regulatory submission process for avacincaptad pegol (ACP, also known as Zimura®) since he joined Iveric Bio in 2020.

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

PARSIPPANY, N.J.--( BUSINESS WIRE )--IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Per the company's agreement with the FDA for rolling NDA review, part 3 of the NDA included chemistry, manufacturing, and controls data.

Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Recent developments on Zimura label improve investor attractiveness. Market for underlying treatments continues to grow with ageing population.

Iveric bio: Building Momentum Around Zimura, Rate Buy

PARSIPPANY, N.J.--( BUSINESS WIRE )--IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,002,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company.

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

PARSIPPANY, N.J.--( BUSINESS WIRE )--IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock being offered. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by the Company.

Iveric Bio Announces Proposed Offering of Common Stock

Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framework, with shares gaining 25% on Friday afternoon. Yesterday, the company disclosed receiving a breakthrough therapy designation for its flagship therapeutic candidate from the Food and Drug Administration (FDA).

Why Is Iveric Bio (ISEE) Stock Up 25% Today?

PARSIPPANY, N.J.--( BUSINESS WIRE )--IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials.

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn Sblendorio - CEO & Director Pravin Dugel - President David Carroll - SVP, CFO & Treasurer Conference Call Participants Kenneth Cacciatore - Cowen and Company Gregory Harrison - Bank of America Merrill Lynch Colleen Kusy - Robert W. Baird & Co. Eliana Merle - UBS Annabel Samimy - Stifel Kambiz Yazdi - Jefferies Michael Ulz - Morgan Stanley David Nierengarten - Wedbush Securities Eddie Hickman - Guggenheim Securities Operator Good day, and welcome to the Iberia Third Quarter 2022 Earnings Conference Call.

IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript

Iveric Bio to Present at Upcoming Investor Conferences

Apellis Pharma

Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash as shares of rival Iveric Bio inched higher. The post Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio appeared first on Investor's Business Daily.

Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio

Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022

AMC Entertainment

Altice USA

Cano Health

Cricut

Eve Holding Inc

Getty Images Holdings Inc

NCR Corporation

Revance Therapeutics

Sotera Health

Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.

These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company's second Phase 3 clinical trial of Zimura, at AAO 2022.

Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.

Why Iveric Bio Stock Is Skyrocketing This Week

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to sham control with statistical significance. NDA filing of Zimura for the treatment of patients with Geographic Atrophy are expected end of Q1 of 2023.

Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura

Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive results from a Phase 3 clinical trial. That trial covered the use of Zimura in treating patients suffering from geographic atrophy (GA).

Why Is Iveric Bio (ISEE) Stock Up 56% Today?

The market looked poised to bounce after the long weekend.

The 2 Stocks Everyone's Talking About Tuesday

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced positive topline results from GATHER2, the Company's second Phase 3 clinical trial of Zimura, for the treatment of GA.

Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pravin U. Dugel, M.D., President, will participate in a panel discussion at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.

Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Adicet Bio, Inc.

Chinook Therapeutics

Kura Oncology

 Pliant Therapeutics

Rocket Pharma

Caribou Biosciences

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

7 Cheap Biotech Stocks to Buy Now

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022.

News for IVERIC bio Inc Stock (ISEE)